Gregg Fonarow MD (@gcfmd) header
Gregg Fonarow MD (@gcfmd) profile picture
Los Angeles, CA
Joined December 2012
Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)Photo by Gregg Fonarow MD (@gcfmd)
Gregg Fonarow MD retweeted
Vaccination Is Heart Failure Care: Closing the Team-Based Delivery Gap The ACC guidance establishes vaccination as part of cardiovascular care. Reliable delivery, however, depends on shared accountability across clinicians and settings. Heart failure specialty teams need not replace primary care; they are well positioned to complement it by recognizing vaccination gaps, serving as trusted messengers who connect immunization to cardiovascular risk, and ensuring that recommendations lead to on-site administration or a closed-loop referral. @gcfmd @SJGreene_md @hfcollaboratory @DrMarthaGulati @Hragy sciencedirect.com/science/ar…
1
9
532
Vaccination Is Heart Failure Care: Closing the Team-Based Delivery Gap “…interdisciplinary teams can turn evidence-based recommendations into documented completion and more reliable patient protection.” sciencedirect.com/science/ar… @JCardFail @ACCinTouch @American_Heart @HFSA
1
13
775
Gregg Fonarow MD retweeted
Dr. Karol Watson (@kewatson) highlights the results of the highly-anticipated Lp(a)HORIZON trial published in @NEJM and presented at #AHA26. Watch the full discussion with Dr. André Sofair and Dr. David Cohen (@djc795) for more key study results: nej.md/4t2Vl2C
7
13
2,100
Gregg Fonarow MD retweeted
Cardiovascular-Kidney-Metabolic Overlap in Patients Hospitalized for Heart Failure In this nationwide cohort of US patients with HF, HF in the absence of other CKM conditions was uncommon, and increasing CKM multimorbidity was associated with increasing clinical risk, especially in HF with reduced EF. @gcfmd @SJGreene_md @DrMarthaGulati @ehj_ed @hfcollaboratory @mvaduganathan jamanetwork.com/journals/jam…
7
11
637
Gregg Fonarow MD retweeted
Only 18.2% of eligible US patients with #HFrEF receive all four foundational therapies (ARNI, beta-blocker, MRA and SGLT2 inhibitor). A national study estimates that closing this gap could prevent 114,000 deaths and 357,000 #HeartFailure hospitalizations each year.
2
6
17
1,169
Gregg Fonarow MD retweeted
National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction Incomplete implementation of quadruple GDMT in HFrEF remains a major modifiable opportunity to reduce preventable deaths and HF hospitalizations in the United States. @JACCJournals @ACCinTouch @gcfmd @SJGreene_md @AndrewJSauer @HFSA jacc.org/doi/10.1016/j.jchf.…
4
8
504
✅ 4 drug classes cut HFrEF deaths: ARNI, BB, MRA, SGLT2i 
❌ 30 others with great rationale failed in Phase 3 RCTs 
🇺🇸 Only 18% get all 4 → ~114K US deaths preventable/yr 
🎯 Implement GDMT with the same intensity we test new drugs 
#HFrEF #CardioTwitter @HFSA @ACCinTouch
3
10
19
1,362
Randomized, double-blinded, adequately powered, controlled trials. There still is no valid substitute. jamanetwork.com/journals/jam…
When in doubt, randomize #cmgsays AI models Non-randomized observational data Mendelian randomization data All these failed to predict that outcomes of a large Phase 3 randomized trial I am a fan of AI tools, but they are no substitute for a randomized trial
1
13
1,202
Gregg Fonarow MD retweeted
Heart failure mortality fell until 2010, then rose about 37% by 2023. 📈 In HF Stats Behind the Numbers, @Dr. Shahzeb Khan explains what’s driving it, why younger adults are affected, and what clinicians can do now. We have the tools to bend the curve. We need to implement them. 🎥 youtu.be/ZfqXmtJoyoE 📊 Explore HF Stats 2026: hfstats.org/?utm_source=x&ut…
1
1
4
437
🧠 FDA approves asundexian (Sunharbo), 1st FXIa inhibitor for 2° stroke prevention 
📊 OCEANIC-STROKE (n=12,327): ischemic stroke 6.2% vs 8.4%, HR 0.74 
🎯 NNT 47 to prevent 1 stroke 
🩸 Major bleeding 1.9% vs 1.7% (NS) 
💊 50 mg daily + antiplatelet 
💲 $748.50/month list
1
26
1
81
5,220
Gregg Fonarow MD retweeted
Stopping GLP-1 treatment linked to twice the risk of heart attack, stroke or death compared with continuing, in people with type 2 diabetes and no cardiovascular disease, according to a new study. Find out more in @LancetRH_Europe: spkl.io/60137wUtS
62
245
92
805
379,113
The FDA approved asundexian, the first factor XIa (FXIa) inhibitor, for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or high risk TIA neurologylive.com/view/fda-a…
1
8
29
1,796
🫀 Does targeting inflammation prevent ASCVD events? Mostly no (so far)🪦 ❌ ZEUS 2026: hs-CRP −64%, IL-6 −76% → HR 0.99, null 
❌ CLEAR SYNERGY, CIRT, LATITUDE, Lp-PLA2… all null 
⚠️ CANTOS & colchicine "wins" contested Inflammation = risk marker, not a proven 🎯 yet
6
9
1
28
4,046
🫀 SELECT vs SYNCHRONIZE-CVOT 3-pt MACE HR: 0.80 (sema) vs 0.84 (survodutide) ➡️ similar direction SYNCHRONIZE was a safety trial: 212 vs 1,270 events, 22 vs 40 mo f/u, ~44% stopped drug 📉 CIs overlap ✅ Not proven superior may not ≠ less effective ⚠️ @TheLancet
1
9
34
2,335
Gregg Fonarow MD retweeted
Among patients with diabetes or atherosclerosis, but without a prior MI or stroke, those with CKD are at high risk for CV outcomes and death. Intensive LDL-C lowering to ~45mg/dL with #evolocumab substantially attenuates this risk. See details online at @JACC. @ebohula #AHA26
3
26
77
4,081
Gregg Fonarow MD retweeted
📌Sim Pub w/ #ScientificSessions26: Can digital health accelerate GDMT optimization? Randomized ENGAGE-HF trial shows improved #GDMT optimization at 90 days: 83.7% vs 74.0% (P=0.010) Greater uptake of MRAs & SGLT2 inhibitors A promising approach to post-discharge HF care
3
6
3
12
1,208
What if we pursued implementation with the same effort as we chase new drugs? 💡 
Class 1 quadruple GDMT for HFrEF, optimally used in US: 
❤️ 113,747 ☠️s prevented 
🏥 864,181 🏨s avoided 
💰 $6.5–16.4B net saved 
💊 ~$290/pt/yr generic 
The breakthrough is already here!
1
8
13
882
Statins ≥70, no ASCVD? 2 RCTs 
▶️ START (STAREE): NNT 37/5.9y to prevent 1 MACE 
⏹️ STOP (STREAM): +1 MI/stroke/death per 40 who stop, 2y 
😐 Avoiding/stopping: no gain in QoL, function, falls, cognition 
⚖️ Trade-off: mild AEs 
🤝 Ask patients what matters most to them
6
27
90
5,037
Gregg Fonarow MD retweeted
#Dapagliflozin for Renal Protection in Heart Transplant Recipients: #DAPARHT Trial 📍 430 heart transplant recipients randomized to dapagliflozin 10 mg vs placebo; median 7 years post-transplant. 📍 Dapagliflozin improved 12-month #eGFR change: +2.0 vs +0.3 mL/min/1.73 m² . Between-group difference: +1.7 mL/min/1.73 m² (95% CI 0.1–3.3; P=0.03) 📍 No unexpected safety signals; adverse events, including infections, were similar between groups. ahajournals.org/doi/10.1161/… #ScientificSessions26 #AHA26 @AHAScience @AHAMeetings @CircAHA #DAPARHT #SGLT2i #HeartTransplant #CardioRenal
2
7
15
908
Gregg Fonarow MD retweeted
Among patients with atherosclerosis or high-risk diabetes, but without a history of prior stroke, intensive LDL-C lowering with #evolocumab down to ~45 mg/dL reduced the incidence of a first stroke in the VESALIUS-CV study. @ebohula #AHA26
3
9
2
19
2,340